Cantargia announces that the European Patent Office has granted the company’s patent application on the product candidate CAN04.

CAN04 is targeted against the molecule IL1RAP expressed in a large number of cancer diseases. The formal approval follows the intention to grant that EPO issued in April 2017.

The patent application with number 15714603.6 which was granted by the EPO, concerns the company’s product candidate CAN04. The patent protects CAN04 both as a substance as well for cancer treatment. The patent gives protection in Europe until 2035. In addition to the patent granted in Europe, a notice of allowance was obtained in the USA in June 2017. The application has also been submitted in a large number of additional territories such as Japan and China.

“A granted composition of matter patent in Europe is a central component in a commercialization strategy for  CAN04”, says Göran Forsberg, CEO. “Cantargia is in a unique and strong position as we have granted patents both for our product candidate as well as the target molecule.”